Autolus Therapeutics plc (AUTL) shareholders
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| MAK Capital Fund LP Joint filing with Mak Capital One LLC (12.60%), Kaufman Michael A (12.60%) | 33,621,487 | 12.60% | 13G (passive) amendment | Mar 31, 2026 |
| Roel Bulthuis Joint filing with Syncona Portfolio Limited (10.80%), Syncona Holdings Limited (10.80%) and 4 more | 28,821,053 | 10.80% | 13G (passive) amendment | Mar 31, 2025 |
| Michael A. Kaufman Joint filing with MAK Capital Fund LP (10.10%), MAK Capital One L.L.C. (10.10%) | 26,887,508 | 10.10% | 13G (passive) amendment | Dec 1, 2025 |
| Blackstone Inc. Joint filing with BXLS V - Autobahn L.P. (7.60%), Blackstone Life Sciences Associates V (CYM) L.L.C. (7.60%) and 5 more | 20,485,611 | 7.60% | 13D (active) amendment | Nov 6, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (5.94%) | 15,800,000 | 5.94% | 13G (passive) amendment | Mar 31, 2026 |
| MAK Capital One L.L.C. Joint filing with MAK Capital Fund LP (5.80%), Michael A. Kaufman (5.80%) | 15,408,638 | 5.80% | 13G (passive) | Jun 17, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (5.64%) | 15,000,000 | 5.64% | 13G (passive) amendment | Jun 30, 2026 |
| PPF Group a.s. Joint filing with Renata Kellnerova (5.60%), AMALAR HOLDING s.r.o. (5.60%) and 1 more | 14,782,275 | 5.60% | 13D (active) amendment | Aug 27, 2026 |
| Ppf Biotech B.V. Joint filing with Renata Kellnerova (5.50%), Ppf Group N.V. (5.50%) | 14,612,275 | 5.50% | 13D (active) amendment | Mar 21, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AUTL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mak Capital One LLC | 33,621,487 | 12.63% | $53.79M | – | 7.54% |
| Blackstone Inc. | 20,485,611 | 7.70% | $32.78M | – | 0.10% |
| Syncona Portfolio Ltd | 16,640,720 | 6.25% | $26.63M | – | 100.00% |
| Armistice Capital, LLC | 15,000,000 | 5.64% | $24.00M | −800,000 | 0.29% |
| TFG Asset Management GP Ltd | 9,500,000 | 3.57% | $15.20M | – | 2.39% |
| Schroder Investment Management Group | 7,833,282 | 2.94% | $12.92M | −1,656,063 | 0.01% |
| Frazier Life Sciences Management, L.P. | 4,447,910 | 1.67% | $7.12M | – | 0.15% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3,361,156 | 1.26% | $5.38M | – | 0.01% |
| Laurion Capital Management LP | 3,316,626 | 1.25% | $5.31M | – | 0.14% |
| Renaissance Technologies LLC | 1,984,700 | 0.75% | $3.18M | −314,799 | 0.00% |
| Bank Of America Corp /De/ | 1,605,092 | 0.60% | $2.57M | −239,579 | 0.00% |
| BlackRock, Inc. | 1,603,458 | 0.60% | $2.57M | +122,726 | 0.00% |
| UBS Group AG | 1,516,991 | 0.57% | $2.43M | +211,212 | 0.00% |
| Morgan Stanley | 1,260,832 | 0.47% | $2.02M | +319,009 | 0.00% |
| Millennium Management LLC | 1,224,818 | 0.46% | $1.96M | +1,020,090 | 0.00% |
| Cetera Investment Advisers | 1,157,324 | 0.43% | $1.85M | +28,250 | 0.00% |
| Balyasny Asset Management L.P. | 972,748 | 0.37% | $1.56M | +1,057 | 0.00% |
| JPMorgan Chase & Co | 913,239 | 0.34% | $1.51M | −22,164 | 0.00% |
| Alphabet Inc. | 698,262 | 0.26% | $1.12M | – | 0.00% |
| Citadel Advisors LLC | 695,890 | 0.26% | $1.11M | +236,486 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 84 | 132M | 49.7% | 10 / 28 | 21 / 10 | 3M | 5M |
| Q1 2026 | 84 | 134M | 50.5% | 9 / 22 | 30 / 13 | 6M | 11M |
| Q4 2025 | 89 | 139M | 52.4% | 14 / 25 | 29 / 19 | 13M | 16M |
| Q3 2025 | 96 | 146M | 54.7% | 14 / 35 | 23 / 12 | 38M | 58M |
| Q2 2025 | 94 | 166M | 62.4% | 19 / 33 | 26 / 20 | 24M | 26M |
| Q1 2025 | 95 | 168M | 63.2% | 8 / 30 | 33 / 23 | 13M | 14M |
| Q4 2024 | 110 | 168M | 63.3% | 23 / 34 | 31 / 14 | 13M | 24M |
| Q3 2024 | 101 | 180M | 67.6% | 7 / 31 | 36 / 16 | 20M | 14M |
| Q2 2024 | 111 | 179M | 67.1% | 15 / 39 | 31 / 24 | 29M | 27M |
| Q1 2024 | 120 | 177M | 66.6% | 27 / 46 | 27 / 6 | 71M | 9M |
| Q4 2023 | 99 | 116M | 43.6% | 34 / 21 | 19 / 5 | 20M | 15M |
| Q3 2023 | 71 | 111M | 41.6% | 10 / 14 | 25 / 8 | 8M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
8 funds held AUTL in Q2 2026, 92% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AUTL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Biotechnology ETF | 1,428,929 | 0.54% | $2.29M | 0.03% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 120,878 | 0.05% | $226.04K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 84,409 | 0.03% | $135.05K | 0.02% | Jun 30, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 44,936 | 0.02% | $84.03K | 0.44% | May 31, 2026 |
| ActivePassive International Equity ETF | 22,753 | 0.01% | $42.55K | 0.00% | May 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 10,575 | 0.00% | $19.78K | 0.03% | May 31, 2026 |
| ProShares Ultra Nasdaq Biotechnology | 7,414 | 0.00% | $13.86K | 0.02% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -14,000 | -0.01% | -$22.40K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christian Itin | Chief Executive Officer, Director | 1,116,009 | 0.42% | Mar 18, 2026 |
| Cintia Piccina | U.S. CCO & Country Gen Manager | 13,287 | 0.00% | Sep 3, 2026 |
| Christopher Andrew Vann | Chief Operating Officer | 152,211 | 0.06% | Mar 18, 2026 |
| Alexander Swan | Chief Human Resources Officer | – | – | Mar 18, 2026 |
| Alex Driggs | SVP, Legal Affairs and GC | – | – | Mar 18, 2026 |
| Miranda Suzette Neville | Chief Technology Officer | – | – | Mar 18, 2026 |
| Robert Dolski | Chief Financial Officer | – | – | Mar 18, 2026 |
| Patrick Paul McIlvenny | SVP Finance | – | – | Mar 18, 2026 |
| Christopher Michael James Williams | Chief Business Officer | 8,198 | 0.00% | Mar 18, 2026 |
| Matthias Will | Chief Development Officer | – | – | Mar 18, 2026 |
| Linda Bain | Director | – | – | Jul 1, 2026 |
| Cynthia M. Butitta | Director | – | – | Jul 1, 2026 |
| Ryan Richardson | Director | – | – | Jul 1, 2026 |
| Robert Azelby | Director | – | – | Jul 1, 2026 |
| Robert Iannone | Director | – | – | Jul 1, 2026 |
| Elisabeth Leiderman | Director | – | – | Jul 1, 2026 |
| Michael W. Bonney | Director | – | – | Jul 1, 2026 |
| Madduri Ravin Rao | Director | – | – | Jul 1, 2026 |
| William D. Young | Director | – | – | Jul 1, 2026 |
| John E. Berriman | Director | 136,331 | 0.05% | Mar 18, 2026 |
| Martin Anton Pule | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cintia Piccina U.S. CCO & Country Gen Manager | Sep 2, 2026 | Sale | −6,713 | $2.34 | $15.71K | 13,287 |
| Cintia Piccina U.S. CCO & Country Gen Manager | Sep 1, 2026 | Option exercise | +20,000 | $2.35 | $47.00K | 20,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Autolus Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,803 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cintia Piccina Officer | Sep 2, 2026 | 6,713 | $15.68K | Sep 2, 2026 | Restricted Stock Vesting |
| Martin Anton Pule Officer | Sep 16, 2024 | 698,741 | $2.96M | Sep 16, 2024 | Shares were issued on foundation of the company and converted from private to public shares at IPO |
See a number that looks wrong?